Alzheimer's vaccine results boost Elan, Wyeth

[industry_news]

Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's vaccine. The study did not attain statistical significance on the efficacy endpoints in the overall study population, but the vaccine helped patients without a gene known as ApoE4. About 70 percent of Alzheimer's sufferers don't have the ApoE4 gene. A spokesperson for the company said the results support the decision to move bapineuzumab into Phase II trials. Back in April the companies suspended a mid-stage study of the vaccine after seeing one of the patients in the study develop skin lesions.
- see this release for more
Related Articles:
Wyeth, Elan suspend Alzheimer's vaccine study
Wyeth stumbles badly trying to develop new drugs
Wyeth, Elan advance Phase III Alzheimer's trial


More...